Mano Nakamura
Overview
Explore the profile of Mano Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James M, Nakamura M, Whittaker S, Morris S
Br J Dermatol
. 2024 Mar;
190(6):929-930.
PMID: 38470968
No abstract available.
2.
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, et al.
Nat Commun
. 2023 Jul;
14(1):4180.
PMID: 37491373
All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report...
3.
Crescioli S, Correa I, Ng J, Willsmore Z, Laddach R, Chenoweth A, et al.
Nat Commun
. 2023 Jun;
14(1):3378.
PMID: 37291228
B cells are known to contribute to the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not been characterized in these cancers to detail....
4.
Chauhan J, Grandits M, Palhares L, Mele S, Nakamura M, Lopez-Abente J, et al.
Nat Commun
. 2023 May;
14(1):2192.
PMID: 37185332
Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective...
5.
Bax H, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, et al.
Br J Cancer
. 2022 Nov;
128(2):342-353.
PMID: 36402875
Background: Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the...
6.
Egbuniwe I, Harris R, Nakamura M, Nestle F, Akbar A, Karagiannis S, et al.
J Invest Dermatol
. 2021 Aug;
142(3 Pt A):726-731.e4.
PMID: 34450137
No abstract available.
7.
Willsmore Z, Harris R, Crescioli S, Hussein K, Kakkassery H, Thapa D, et al.
Front Immunol
. 2021 Feb;
11:622442.
PMID: 33569063
The contributions of the humoral immune response to melanoma are now widely recognized, with reports of positive prognostic value ascribed to tumor-infiltrating B cells (TIL-B) and increasing evidence of B...
8.
Willsmore Z, Coumbe B, Crescioli S, Reci S, Gupta A, Harris R, et al.
Eur J Immunol
. 2021 Jan;
51(3):544-556.
PMID: 33450785
Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and the Programmed Death Receptor 1 (PD-1) are immune checkpoint molecules that are well-established targets of antibody immunotherapies for the management of malignant melanoma. The...
9.
Nakamura M, Souri E, Osborn G, Laddach R, Chauhan J, Stavraka C, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33203088
IgE contributes to host-protective functions in parasitic and bacterial infections, often by monocyte and macrophage recruitment. We previously reported that monocytes contribute to tumour antigen-specific IgE-mediated tumour growth restriction in...
10.
Chauhan J, McCraw A, Nakamura M, Osborn G, Sow H, Cox V, et al.
Antibodies (Basel)
. 2020 Oct;
9(4).
PMID: 33081206
Immunoglobulin E (IgE) antibodies are well known for their role in allergic diseases and for contributions to antiparasitic immune responses. Properties of this antibody class that mediate powerful effector functions...